Determine the duration and consistency of the reduction in BP over the course of a day, relative to placebo, after 6 weeks of treatment with LY518674 when taken once daily

Evaluate the population dose and exposure response relationships of LY518674 for lowering the mean SBP and DBP during the 24 hour period, using ABPM during a 6 week treatment period

Evaluate the population dose, exposure, and time response relationships of LY518674 for lowering the mean SBP and DBP during the 8 hour awake period, using ABPM during a 6 week treatment and following cessation of dosing

Compare the effect of LY518674 on CBPM SBP and DBP with that of placebo

Evaluate the safety and tolerability effects of LY518674, relative to placebo, in patients with mild hypertension

Estimated Enrollment:

153

Study Start Date:

September 2006

Study Completion Date:

November 2006

Eligibility

Ages Eligible for Study:

18 Years to 70 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Are men and women between 18 and 70 years of age, inclusive

Have given signed informed consent to participate in this study

Are diagnosed with mild essential hypertension at screening (currently untreated or treated with monotherapy)

Exclusion Criteria:

Secondary or malignant hypertension

Have or have had a history of hyperlipidemia within 3 months of screening requiring treatment

Any previous cardiovascular disease other than hypertension

Type 1 or 2 diabetes

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00374855